

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

RECEIVED NOV 26 2001 File Information Unit		In re Application of	
		Application Number 07/310,252	Filed 2/13/89
Group Art Unit 184	Examiner He		
		Paper No. 35	HL2
<p>Assistant Commissioner for Patents Washington, DC 20231</p> <p>I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)</p> <p><input type="checkbox"/> (A) referred to in United States Patent Number <u>5,693,761</u> column _____.</p> <p><input type="checkbox"/> (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____.</p> <p><input type="checkbox"/> (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or</p> <p><input type="checkbox"/> (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.</p> <p>Please direct any correspondence concerning this request to the following address:</p> <hr/> <hr/> <hr/> <hr/> <p><u>Reggie Mitchell</u> Signature</p> <p><u>11/26/01</u> Date</p> <p>Typed or printed name</p> <p>FOR PTO USE ONLY</p> <p>Approved by: _____ (Initials)</p> <p>Unit _____</p>			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

United States Patent [19]
Queen et al.

[11] **Patent Number:** 5,693,761
[45] **Date of Patent:** Dec. 2, 1997

[54] **POLYNUCLEOTIDES ENCODING
IMPROVED HUMANIZED
IMMUNOGLOBULINS**

[75] **Inventors:** Cary L. Queen, Los Altos; William P. Schneider, Mountain View; Harold E. Selick, Belmont, all of Calif.

[73] **Assignee:** Protein Design Labs, Inc., Mountain View, Calif.

[21] **Appl. No.:** 474,040

[22] **Filed:** Jun. 7, 1995

Related U.S. Application Data

[62] **Division of Ser. No. 634,278, Dec. 19, 1990, Pat. No. 5,530,101, which is a continuation of Ser. No. 590,274, Sep. 28, 1990, abandoned, and a continuation of Ser. No. 310,252, Feb. 13, 1989, abandoned, which is a continuation of Ser. No. 290,975, Dec. 28, 1988, abandoned.**

[51] **Int. Cl⁶** C07H 21/04

[52] **U.S. Cl.** 536/23.53; 530/387.3; 435/320.1; 435/252.3

[58] **Field of Search** 536/23.53; 530/387.3; 435/320.1, 252.3

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,578,335	3/1986	Urdal et al.	530/351
4,816,397	3/1989	Boss et al.	435/68
4,816,565	3/1989	Honjo et al.	435/69.1
4,816,567	3/1989	Cabilly et al.	530/387
4,845,198	7/1989	Urdal et al.	530/387
4,867,973	9/1989	Goers et al.	424/85.91
5,198,359	3/1993	Taniguchi et al.	435/252.3
5,225,539	7/1993	Winter	530/387.3
5,476,786	12/1995	Huston et al.	435/85.8

FOREIGN PATENT DOCUMENTS

0 120 694	10/1984	European Pat. Off.
0171496	2/1986	European Pat. Off.
0173494	3/1986	European Pat. Off.
0184187	6/1986	European Pat. Off.
0256654	7/1987	European Pat. Off.
0239400	9/1987	European Pat. Off.
0266663	6/1988	European Pat. Off.
0 323 806	7/1989	European Pat. Off.
0 328 404	8/1989	European Pat. Off.
0 365 209	4/1990	European Pat. Off.
0 365 997	5/1990	European Pat. Off.
0 125 023	6/1991	European Pat. Off.
0460167	12/1991	European Pat. Off.
2188941	10/1987	United Kingdom
8928874	12/1989	United Kingdom
WO 86/05513	9/1986	WIPO
WO 87/02671	5/1987	WIPO
WO 88/09344	12/1988	WIPO
WO 89/01783	3/1989	WIPO
91/09967	7/1991	WIPO

OTHER PUBLICATIONS

Better et al. "Escherichia coli Secretion of an Active Chimeric Antibody Fragment," *Science*, 240:1041-1043 (1988).

Bird et al., "Single-Chain Antigen-Binding Proteins," *Science*, 242:423-426 (1988).

Boulianne et al., "Production of functional chimeric mouse/human antibody," *Nature*, 312:643-646 (1984).

Carter et al., "Humanization of an anti-p185^{HER2} antibody for human cancer therapy," *Proc. Natl. Acad. Sci.*, 89:4285-4289 (1992).

Chothia, C. and A.M. Lesk, "Canonical Structures for the Hypervariable Regions of Immunoglobulins," *J. Mol. Biol.*, 196:901-917 (1987).

Co et al., "Humanized antibodies for antiviral therapy," *Proc. Natl. Acad. Sci.*, 88:2869-2873 (1991).

Co et al., "Chimeric and humanized antibodies with specificity for the CD33 antigen," *J. Immunol.*, 148:1149-1154 (1992).

Daugherty et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expansion of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," *Nuc. Acids Res.*, 19:2471-2476 (1991).

Ellison et al., "The nucleotide sequence of a human immunoglobulin c(gamma)₁ gene," *Nucleic Acids Res.*, 10:4071-4072 (1982).

Farrar, J., "The biochemistry, biology, and the role of interleukin-2 in the induction of cytotoxic T cell and antibody-forming B cell receptors," *Immunol. Rev.*, 63:129-166 (1982).

Foote et al., "Antibody framework residues affecting the conformation of hypervariable loops," *J. Mol. Biol.*, 224:487-499 (1992).

Gorman et al., "Reshaping a therapeutic CD4 antibody," *Proc. Natl. Acad. Sci.*, 88:4181-4185 (1991).

(List continued on next page.)

Primary Examiner—Lila Feisee

Assistant Examiner—Julie E. Reeves

Attorney, Agent, or Firm—Townsend and Townsend and Crew LLP

[57] **ABSTRACT**

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.